| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4239646 | Journal of Vascular and Interventional Radiology | 2012 | 15 Pages |
Abstract
LTLD can be safely administered systemically at the MTD (50 mg/m2) in combination with RF ablation, with limited and manageable toxicity. Further evaluation of this agent combined with RF ablation is warranted to determine its role in the management of liver tumors.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Radiology and Imaging
Authors
Bradford J. MD, Ronnie T. MD, Julia K. RN, MS, MBA, Matthew R. PhD, K.K. MD, Michelle RN, Geoffrey RN, Sergio MD, Ziv MD, Michael PharmD, Christopher D.V. PhD, Raj MBA, Steven K. MD,